Defects in spliceosomal machinery: A new pathway of leukaemogenesis

British Journal of Haematology

Volumn 158, Issue 2, 2012, Pages 165-173

  Maciejewski, Jaroslaw P ^a   Padgett, Richard A ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Defects; Leukaemogenesis; Spliceosomal machinery

Indexed keywords

ISOPROTEIN;

ALTERNATIVE RNA SPLICING; BONE MARROW TUMOR; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC VALUE; GAIN OF FUNCTION MUTATION; GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC EPIGENESIS; HAPLOINSUFFICIENCY; HEMATOLOGIC MALIGNANCY; HUMAN; INTRON RETENTION; LEUKEMOGENESIS; MISSENSE MUTATION; MOLECULAR PATHOLOGY; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; RNA SPLICING; SF3B1 GENE; SOMATIC MUTATION; SPLICEOSOME; SPLICING DEFECT; SRSF1 GENE; SRSF2 GENE; SUPPRESSOR GENE; U2AF1 GENE; U2AF1L4 GENE; ZRSR2 GENE;

CELL TRANSFORMATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; MUTATION; RNA SPLICING; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SPLICEOSOMES;

EID: 84863481799     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09158.x     Document Type: Review

References (34)

1. Albert, B.J., Sivaramakrishnan, A., Naka, T., Czaicki, N.L. & Koide, K. (2007) Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. Journal of the American Chemical Society, 129, 2648-2659.
2. Albert, B.J., McPherson, P.A., O'Brien, K., Czaicki, N.L., Destefino, V., Osman, S., Li, M., Day, B.W., Grabowski, P.J., Moore, M.J., Vogt, A. & Koide, K. (2009) Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Molecular Cancer Therapeutics, 8, 2308-2318.
3. Corrionero, A., Minana, B. & Valcarcel, J. (2011) Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes & Development, 25, 445-459.
4. Fu, Y., Masuda, A., Ito, M., Shinmi, J. & Ohno, K. (2011) AG-dependent 3′-splice sites are predisposed to aberrant splicing due to a mutation at the first nucleotide of an exon. Nucleic Acids Research, 39, 4396-4404.
5. Graubert, T.A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C.L., Shao, J., Krysiak, K., Harris, C.C., Koboldt, D.C., Larson, D.E., McLellan, M.D., Dooling, D.J., Abbott, R.M., Fulton, R.S., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Grillot, M., Baty, J., Heath, S., Frater, J.L., Nasim, T., Link, D.C., Tomasson, M.H., Westervelt, P., DiPersio, J.F., Mardis, E.R., Ley, T.J., Wilson, R.K. & Walter, M.J. (2011) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 44, 53-57.
6. Hirabayashi, S., Flotho, C., Moetter, J., Heuser, M., Hasle, H., Gruhn, B., Klingebiel, T., Thol, F., Schlegelberger, B., Baumann, I., Strahm, B., Stary, J., Locatelli, F., Zecca, M., Bergstraesser, E., Dworzak, M., van den Heuvel-Eibrink, M.M., De Moerloose, B., Ogawa, S., Niemeyer, C.M. & Wlodarski, M.W. (2012) Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood, 119, e96-e99.
7. Isono, K., Mizutani-Koseki, Y., Komori, T., Schmidt-Zachmann, M.S. & Koseki, H. (2005) Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes & Development, 19, 536-541.
8. Kim, H., Hsieh, J.J. & Cheng, E.H. (2009) Deadly splicing: Bax becomes Almighty. Molecular Cell, 33, 145-146.
9. Kuhn, A.N., Van Santen, M.A., Schwienhorst, A., Urlaub, H. & Luhrmann, R. (2009) Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA, 15, 153-175.
10. Li, X. & Manley, J.L. (2005) Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell, 122, 365-378.
11. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J. & Knight, R.; Myelodysplastic Syndrome-003 Study Investigators. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine. 355:1456-1465.
12. Makishima, H. & Maciejewski, J.P. (2011) Pathogenesis and consequences of uniparental disomy in cancer. Clinical Cancer Research, 17, 3913-3923, Epub 2011.
13. Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A.M., Abu Kar, S., Jerez, A., Przychodzen, B., Bupathi, M., Guinta, K., Afable, M.G., Sekeres, M.A., Padgett, R.A., Tiu, R.V. & Maciejewski, J.P. (2012) Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood, 119, 3203-3210.
14. Malcovati, L., Papaemmanuil, E., Bowen, D.T., Boultwood, J., Della Porta, M.G., Pascutto, C., Travaglino, E., Groves, M.J., Godfrey, A.L., Ambaglio, I., Gallì, A., Da Vià, M.C., Conte, S., Tauro, S., Keenan, N., Hyslop, A., Hinton, J., Mudie, L.J., Wainscoat, J.S., Futreal, P.A., Stratton, M.R., Campbell, P.J., Hellström-Lindberg, E. & Cazzola, M.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood, 118, 6239-6246.
15. Massiello, A., Roesser, J.R. & Chalfant, C.E. (2006) SAP155 Binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5′ splice site selection of Bcl-x pre-mRNA. FASEB J, 20, 1680-1682.
16. Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K., Yomoda, J., Murray, M.V., Kimura, H., Furuichi, K., Shibuya, H., Krainer, A.R., Suzuki, M. & Hagiwara, M. (2004) Manipulation of alternative splicing by a newly developed inhibitor of Clks. Journal of Biological Chemistry, 279, 24246-24254.
17. Muramatsu, H., Makishima, H. & Maciejewski, J.P. (2012) Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Seminars in Oncology, 39, 67-73.
18. Pacheco, T.R., Moita, L.F., Gomes, A.Q., Hacohen, N. & Carmo-Fonseca, M. (2006) RNA interference knockdown of hU2AF35 impairs cell cycle progression and modulates alternative splicing of Cdc25 transcripts. Molecular Biology of the Cell, 17, 4187-4199.
19. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., Godfrey, A.L., Rapado, I., Cvejic, A., Rance, R., McGee, C., Ellis, P., Mudie, L.J., Stephens, P.J., McLaren, S., Massie, C.E., Tarpey, P.S., Varela, I., Nik-Zainal, S., Davies, H.R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A.P., Teague, J.W., Baxter, E.J., Score, J., Galli, A., Della Porta, M.G., Travaglino, E., Groves, M., Tauro, S., Munshi, N.C., Anderson, K.C., El-Naggar, A., Fischer, A., Mustonen, V., Warren, A.J., Cross, N.C., Green, A.R., Futreal, P.A., Stratton, M.R. & Campbell, P.J. (2011) Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. New England Journal of Medicine, 365, 1384-1395.
20. Patnaik, M.M., Lasho, T.L., Hodnefield, J.M., Knudson, R.A., Ketterling, R.P., Garcia-Manero, G., Steensma, D.P., Pardanani, A., Hanson, C.A. & Tefferi, A. (2012) SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 119, 569-572.
21. Pilch, B., Allemand, E., Facompre, M., Bailly, C., Riou, J.F., Soret, J. & Tazi, J. (2001) Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Research, 61, 6876-6884.
22. Prasad, J., Colwill, K., Pawson, T. & Manley, J.L. (1999) The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing. Molecular and Cellular Biology, 19, 6991-7000.
23. Quesada, V., Conde, L., Villamor, N., Ordóñez, G.R., Jares, P., Bassaganyas, L., Ramsay, A.J., Beà, S., Pinyol, M., Martínez-Trillos, A., López-Guerra, M., Colomer, D., Navarro, A., Baumann, T., Aymerich, M., Rozman, M., Delgado, J., Giné, E., Hernández, J.M., González-Díaz, M., Puente, D.A., Velasco, G., Freije, J.M., Tubío, J.M., Royo, R., Gelpí, J.L., Orozco, M., Pisano, D.G., Zamora, J., Vázquez, M., Valencia, A., Himmelbauer, H., Bayés, M., Heath, S., Gut, M., Gut, I., Estivill, X., López-Guillermo, A., Puente, X.S., Campo, E. & López-Otín, C. (2011) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics, 44, 47-52.
24. Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., Guarini, A., Del Giudice, I., Cerri, M., Cresta, S., Deambrogi, C., Gargiulo, E., Gattei, V., Forconi, F., Bertoni, F., Deaglio, S., Rabadan, R., Pasqualucci, L., Foà, R., Dalla-Favera, R. & Gaidano, G. (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood, 118, 6904-6908.
25. Shen, H., Zheng, X., Luecke, S. & Green, M.R. (2010) The U2AF35-related protein Urp contacts the 3′ splice site to promote U12-type intron splicing and the second step of U2-type intron splicing. Genes & Development, 24, 2389-2394.
26. Shepard, P.J. & Hertel, K.J. (2009) The SR protein family. Genome Biology, 10, 242.
27. Visconte, V., Makishima, H., Jankowska, A., Szpurka, H., Traina, F., Jerez, A., O'Keefe, C., Rogers, H.J., Sekeres, M.A., Maciejewski, J.P. & Tiu, R.V. (2011) SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia, 26, 542-545.
28. Wachtel, C. & Manley, J.L. (2009) Splicing of mRNA precursors: the role of RNAs and proteins in catalysis. Molecular BioSystems, 5, 311-316.
29. Wahl, M.C., Will, C.L. & Luhrmann, R. (2009) The spliceosome: design principles of a dynamic RNP machine. Cell, 136, 701-718.
30. Wang, E.T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S.F., Schroth, G.P. & Burge, C.B. (2008) Alternative isoform regulation in human tissue transcriptomes. Nature, 456, 470-476.
31. Wang, L., Lawrence, M.S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D.S., Zhang, L., Zhang, W., Vartanov, A.R., Fernandes, S.M., Goldstein, N.R., Folco, E.G., Cibulskis, K., Tesar, B., Sievers, Q.L., Shefler, E., Gabriel, S., Hacohen, N., Reed, R., Meyerson, M., Golub, T.R., Lander, E.S., Neuberg, D., Brown, J.R., Getz, G. & Wu, C.J. (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. New England Journal of Medicine, 365, 2497-2506.
32. Ward, A.J. & Cooper, T.A. (2010) The pathobiology of splicing. The Journal of pathology, 220, 152-163.
33. Will, C.L. & Lührmann, R. (2005) Splicing of a rare class of introns by the U12-dependent spliceosome. Biological Chemistry, 386, 713-724.
34. Yoshida, K, Sanada, M, Shiraishi, Y, Nowak, D, Nagata, Y, Yamamoto, R, Sato, Y, Sato-Otsubo, A, Kon, A, Nagasaki, M, Chalkidis, G, Suzuki, Y, Shiosaka, M, Kawahata, R, Yamaguchi, T, Otsu, M, Obara, N, Sakata-Yanagimoto, M, Ishiyama, K, Mori, H, Nolte, F, Hofmann, WK, Miyawaki, S, Sugano, S, Haferlach, C, Koeffler, HP, Shih, LY, Haferlach, T, Chiba, S, Nakauchi, H, Miyano, S & Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature., 478, 64-9.